Dr. Deborah O'Neil
Chief Executive Officer and Scientific Officer
A biotechnologist with over two decades of experience in the field of anti-infectives research & drug development.
Deborah founded NovaBiotics in 2004. She trained as an immunologist in internationally acclaimed laboratories (University College London, UC San Diego, University of Ghent) before moving to Aberdeen and developing the commercial potential of her platform of novel antibacterial and antifungal therapies, spinning NovaBiotics out of the Rowett Research Institute. Deborah is editor of the European Biopharmaceutical Review and International Pharmaceutical Technology, a member of the Scottish Life Science Industry Leadership Group and sits on the Advisory Board of the Scottish Life Sciences Association. Deborah is also a member of the newly formed Life Sciences board of Opportunity North East and is also a proud Trustee of Crohn’s in Childhood Research Association. In January 2017, Deborah was named as one of the 15 women leaders in European Biotechnology and was Ernst & Young’s UK Healthcare Products & services Entrepreneur of the Year in 2014.
Mr Bryan Bodek
Chairman of the Board
Mr Bryan Bodek joined NovaBiotics Board in 2009. He is CEO of Airline Services and brings more than 30 years experience of advising public and private companies in all aspects of their business.
Bryan's background is in corporate finance/company law and he has served on the boards of three public companies. He has significant experience in leading successful health care licensing/marketing deals and sits on the University of Manchester’s life science and technology spin out panel.
Bryan is 2011 Ernst & Young U.K. Entrepreneur Of The year for business to business goods and services and Airline Services has been a Sunday Times Fastrack 100 Company in 2010 and 2011.
Mr Paul Foulger
Chief Financial Officer
Paul joined the Board in 2016.
Paul is a qualified certified accountant with extensive public and private company experience, having been Finance Director at Venn Life Sciences plc, Elsevier Science, Orogen Gold plc and Porta Communications plc, amongst others. He jointly led a management buy-out of the financial communications company, Hansard Group plc in 2004 and has substantial lead transactional experience including IPO’s, cash shells, reverse takeovers, divestments, over £100m of fundraising, and a number of acquisitions both in the UK/Europe and the US.
More recently, up until Dec 2015, Paul was CFO at AIM listed EKF Diagnostics Holdings plc, the global Point-of-Care medical diagnostics business which has over 80,000 hemaglobin, A1C, glucose and lactate analysers in regular use in more than 100 countries, running more than 50m tests every year.
He is also a non-executive director of Jupiter Diagnostics, a Point-of-Care blood diagnostics business, Arcis Biotechnology, a company focussed on providing nucleic acid sample prep solutions, and Autoclenz, a leading service provider to the UK automotive industry.
Paul holds an MBA from Warwick Business School.
Mr Ian Townsend
Ian joined NovaBiotics Board in 2011
Ian has over 20 years experience in the medical device sector, co-founding orthopaedic manufacturing business, Eurocut Plc, which went on to become The Medical House Plc and was floated on AIM in 2000. After many years as the Chief Executive Ian became Chairman where he remained until the successful sale of Medical House Plc to Consort Plc in 2009.
Ian qualified as a Chartered Accountant in 1976 and worked with KPMG until 1979 when he set up his own practice in Harrogate. Ian is the founder and Chairman of Townsend Investments Ltd and Townsend Family Investments LLP.
Professor Andy Porter
Andy joined NovaBiotics Board in 2009
Andy is a key figure in the UK biotech sector and international biologics sphere. He was Chief Scientific Officer and on the founding team of Haptogen Ltd, a company which Andy had a key role in facilitating a sale of in 2007 to Wyeth Pharmaceuticals, one of the world's leading pharmaceutical and healthcare products companies.
Andy is currently Professor of Biotechnology and Director of the Scottish Biologics Facility, University of Aberdeen. In 2005 he was made the Ernst and Young Plc, Science and Technology Entrepreneur of the Year. He has been a Fellow of the Royal Society of Edinburgh since 2006 and a Fellow of the Society of Biology since 2012.
In 2008 Andy was a co-founder of Grampian BioPartners, an Angel fund that has a focus in Life Sciences. Andy has been a Board member on a number of SME biotech companies in biologics and regenerative medicine including Bioven Europe Ltd.
Grant joined NovaBiotics Board in 2013.
He is a serial entrepreneur and Chartered Insurance Broker; most of his working life being in in the insurance and financial services sectors. Grant led the successful AIM listing of the Broker Network and its subsequent sales to The Towergate Partnership.
Grant remains a Non-executive Director of the Ellis Bates Group of companies, which he cofounded in 1980, and is also Chairman of specialist fire and security provider Assured Fire & Security Ltd.
He also serves as a mentor to several small companies.